Review
Health Care Sciences & Services
Evanthia P. Perikleous, Paschalis Steiropoulos, Evangelia Nena, Emmanouil Paraskakis
Summary: Childhood asthma is a common and complex chronic condition in children, and the management of severe asthma remains challenging. The use of biologic agents has shown promise in treating severe childhood asthma, but long-term effects are still unclear. Further research is needed to determine the most effective biologic agents and predictors of treatment response for pediatric patients.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Medicine, General & Internal
Guy G. Brusselle, Gerard H. Koppelman
Summary: Biologic therapies may be necessary to reduce the disease burden and risks for severe asthma patients. This review discusses the mechanisms, efficacy, and safety of biologics for severe asthma.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Juan Liu, Bin Di, Li-li Xu
Summary: Inflammatory bowel disease (IBD) is effectively treated with multiple options, and new therapies are actively being explored to provide more choices. Biologic agents and small molecule drugs for ulcerative colitis and Crohn's disease have evolved to have fewer side effects and more accurate targeting. Novel inhibitors targeting cytokines, integrins, cytokine signaling pathways, and cell signaling receptors have become preferred treatments for many IBD patients. Conventional therapies continue to show therapeutic efficacy, particularly when combined with drug therapy.
CYTOKINE & GROWTH FACTOR REVIEWS
(2023)
Article
Biology
Teodora-Larisa Timis, Lehel Beni, Teodora Mocan, Ioan-Alexandru Florian, Remus-Ioan Orasan
Summary: This study aimed to evaluate the effect of biologic therapies on both disease severity and psychological comorbidity in psoriasis patients. The study found that biologic therapy can significantly reduce disease severity and improve depression and anxiety symptoms in patients.
Review
Medicine, Research & Experimental
Xue Wu, Mengying Tao, Ling Zhu, Ting Zhang, Ming Zhang
Summary: Non-infectious uveitis (NIU) is an eye disorder characterized by inflammation, primarily affecting people of working age. Accurate diagnosis and targeted treatment are crucial for improving patient prognosis.
CLINICAL AND EXPERIMENTAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
M. Ellrichmann, J. Bethge, J. Boesenkoetter, C. Conrad, R. Noth, T. Bahmer, S. Nikolaus, K. Aden, S. Zeissig, S. Schreiber
Summary: A prospective study revealed significant obstructive abnormalities in pulmonary function tests (PFT) of patients with active inflammatory bowel disease (IBD), which are related to inflammatory activity and can be improved with anti-TNF therapy. Pulmonary obstruction and potentially chronic bronchopulmonary inflammation are overlooked issues in active IBD, possibly overshadowed by intestinal symptoms.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Pediatrics
Anna Buczynska, Urszula Grzybowska-Chlebowczyk
Summary: This retrospective cohort study aimed to predict subsequent biologic therapy in pediatric IBD patients by identifying parameters measured at diagnosis. Factors such as perianal disease, complicated disease behavior, high inflammation index, and hypoalbuminemia were found to be significantly correlated with biologic therapy. The study also identified the significance of IgA, L4a-L4b in Crohn's disease and hypoalbuminemia in ulcerative colitis.
Review
Medicine, General & Internal
Daniel C. Baumgart, Catherine Le Berre
Summary: This review discusses newer biologic and small-molecule therapies for inflammatory bowel disease, emphasizing the importance of achieving clinical and endoscopic remission as well as more precise molecular targeting of inflammatory cascades.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Roberto Berte, Stefano Mazza, Marta Rachele Stefanucci, Daniele Noviello, Stefania Costa, Clorinda Ciafardini, Erika Mileti, Marina Mapelli, Sebastiano Pasqualato, Sergio Pinto, Agnese Favale, Maurizio Vecchi, Markus F. Neurath, Raja Atreya, Massimo Claudio Fantini, Federica Facciotti, Flavio Caprioli
Summary: The seroprevalence of SARS-CoV-2 in IBD patients treated with biologic therapy reflects values measured in the local general population. Specific symptoms and contact history with SARS-CoV-2-infected individuals strongly increase the likelihood of SARS-CoV-2 seropositivity.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Multidisciplinary Sciences
Juan Carlos Nieto-Gonzalez, Laura Trives-Folguera, Alejandra Melgarejo-Ortuno, Aranzazu Ais, Belen Serrano-Benavente, Maria Sanjurjo, Jose Maria Alvaro-Gracia, Indalecio Monteagudo Saez
Summary: This study found that both persistence and adherence to biological therapy were remarkably high in JIA patients, and adherence to biological treatments could be related to a higher probability of patients achieving remission criteria within 6 months.
SCIENTIFIC REPORTS
(2021)
Review
Biochemistry & Molecular Biology
Niranjan G. Kotla, Yury Rochev
Summary: The pathogenesis of inflammatory bowel disease (IBD) is characterized by gut mucosal inflammation, epithelial damage, and dysbiosis, resulting in a disturbed gut mucosal barrier. Current treatment regimens focus on symptom relief but do not address mucosal epithelial repair, barrier homeostasis, or intestinal dysbiosis. Efforts to identify new therapeutic modalities to enhance gut barrier functions are still in the early developmental stage and have not been entirely successful. In this review, we discuss conventional therapies, the potential role of gut barrier-protecting agents, and biomaterial strategies related to combination therapies that may lead to the development of new therapeutic approaches for IBD.
TRENDS IN MOLECULAR MEDICINE
(2023)
Review
Ophthalmology
Jurgen Sota, Matteo-Maria Girolamo, Bruno Frediani, Gian Marco Tosi, Luca Cantarini, Claudia Fabiani
Summary: Scleritis encompasses a spectrum of ocular conditions, with severe forms being difficult to treat and often associated with systemic diseases. Biologic agents have shown promise in managing non-infectious scleritis, providing targeted and effective treatment options. Further research is needed to fully understand the role of biologic agents in personalized medicine for scleritis.
OPHTHALMOLOGY AND THERAPY
(2021)
Review
Respiratory System
S. Ottaviani, M. Forien
Summary: Though biological agents have improved the prognosis of chronic inflammatory disorders, patient compliance with these treatments remains a challenge. Compliance is influenced by factors such as treatment efficacy, patient-related issues, and the patient-physician relationship. Educational measures, like patient education, have been shown to enhance patient knowledge, leading to better adherence and compliance.
REVUE DES MALADIES RESPIRATOIRES
(2021)
Article
Food Science & Technology
Lenycia de Cassya Lopes Neri, Monica Guglielmetti, Valentina De Giorgis, Ludovica Pasca, Martina Paola Zanaboni, Claudia Trentani, Elena Ballante, Serena Grumi, Cinzia Ferraris, Anna Tagliabue, KDTs Delphi Validation Study Grp
Summary: This study adapted and validated the Brazilian adherence questionnaire iKetoCheck into the Italian version for evaluating the adherence to ketogenic dietary therapies in Italian drug-resistant epilepsy or GLUT1 deficiency patients. The iKetoCheck is a valid tool consisting of 10 questions that assess various aspects of adherence. It can provide valuable information to improve patient management and optimize the effectiveness of ketogenic dietary therapies.
Article
Surgery
Matteo Mombelli, Brian M. Lang, Dionysios Neofytos, John-David Aubert, Christian Benden, Christoph Berger, Katia Boggian, Adrian Egli, Paola M. Soccal, Laurent Kaiser, Cedric Hirzel, Manuel Pascual, Michael Koller, Nicolas J. Mueller, Christian van Delden, Hans H. Hirsch, Oriol Manuel
Summary: The study described the epidemiology and outcomes of respiratory viral infection (RVI) in solid organ transplant (SOT) recipients in Switzerland. The research found that RVI caused important morbidity and may affect long-term outcomes, highlighting the need for improved preventive strategies.
AMERICAN JOURNAL OF TRANSPLANTATION
(2021)
Letter
Gastroenterology & Hepatology
Byron P. Vaughn
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie Long, Matthieu Allez, Pascal Juillerat, Alessandro Armuzzi, Edward Loftus, Elham Ostad-Saffari, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Stuart Lacey, William J. Sandborn
Summary: This study evaluated the efficacy and safety of etrolizumab in patients with moderately to severely active ulcerative colitis who had been previously treated with anti-TNF agents. The results showed that etrolizumab significantly improved remission rates at week 14 compared to placebo, but there was no significant difference between the two groups in remission rates at week 66.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
David T. Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham Radford-Smith, Peter D. R. Higgins, Daniel S. Mishkin, Pablo Arrisi, Astrid Scalori, Young S. Oh, Swati Tole, Akiko Chai, Kirsten Chamberlain-James, Stuart Lacey, Jacqueline McBride, Julian Panes
Summary: Etrolizumab showed superiority over placebo in inducing remission in HIBISCUS I, but not in HIBISCUS II. Etrolizumab was well tolerated in both studies.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Severine Vermeire, Peter L. Lakatos, Timothy Ritter, Stephen Hanauer, Brian Bressler, Reena Khanna, Kim Isaacs, Saumin Shah, Alysha Kadva, Helen Tyrrell, Young S. Oh, Swati Tole, Akiko Chai, Jennifer Pulley, Christopher Eden, Wenhui Zhang, Brian G. Feagan
Summary: This study evaluated the efficacy and safety of etrolizumab for maintenance of remission in patients with moderately to severely active ulcerative colitis. The results showed no significant differences between maintenance etrolizumab and placebo in achieving remission at week 62 among patients with a clinical response at week 10. Etrolizumab was well tolerated in this population, with no new safety signals identified.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2022)
Article
Immunology
Elizabeth S. Aby, Byron P. Vaughn, Eva A. Enns, Radha Rajasingham
Summary: This study assessed the cost-effectiveness of fecal microbiota transplantation (FMT) for first recurrent Clostridioides difficile infection (CDI). The findings indicate that FMT is a cost-effective treatment strategy for first recurrent CDI.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Nutrition & Dietetics
Levi Teigen, Prince P. Mathai, Sharon Lopez, Michael Matson, Baila Elkin, Daria Kozysa, Amanda J. Kabage, Matthew Hamilton, Byron P. Vaughn, Michael J. Sadowsky, Alexander Khoruts
Summary: This study aimed to determine the effect of short-term plant- and animal-based eating patterns on ex vivo fecal H2S production in healthy human volunteers. The results showed that compared to animal-based diet, plant-based diet resulted in lower H2S production in most healthy individuals, although there were substantial individual variations. Taxonomic differences were observed between responders and non-responders, suggesting potential individualized H2S responsiveness to diet.
CLINICAL NUTRITION
(2022)
Editorial Material
Gastroenterology & Hepatology
Elizabeth S. Aby, Shahnaz Sultan, Byron P. Vaughn
Letter
Infectious Diseases
N. O'Morain, R. Stack, J. Doherty, M. Tosetto, A. Garcia Leon, P. Mallon, G. Doherty
JOURNAL OF INFECTION
(2022)
Article
Gastroenterology & Hepatology
Byron P. Vaughn, Monika Fischer, Colleen R. Kelly, Jessica R. Allegretti, Carolyn Graiziger, Juana Thomas, Emma McClure, Amanda J. Kabage, Alexander Khoruts
Summary: This study aimed to evaluate the safety and effectiveness of capsule FMT (cap-FMT) and colonoscopy FMT (colo-FMT) for multiply recurrent Clostridioides difficile infections (rCDIs). The results showed that cap-FMT has a similar safety and effectiveness profile compared with colo-FMT, without the procedural risks of colonoscopy.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Editorial Material
Gastroenterology & Hepatology
Kanwarpreet Tandon, Alan C. Moss
FRONTLINE GASTROENTEROLOGY
(2023)
Letter
Dermatology
Nicole Fagan, Glen A. Doherty, Nekma Meah, Rodney Sinclair, Dmitri Wall
BRITISH JOURNAL OF DERMATOLOGY
(2023)
Letter
Gastroenterology & Hepatology
Byron P. Vaughn, Alexander Khoruts
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Andres Yarur, Maria Abreu, Parakkal Deepak, Poonam Beniwal-Patel, Konstantinos Papamichael, Byron Vaughn, Alexandra Bruss, Shaina Sekhri, Andrea Moosreiner, Phillip Gu, William Kennedy, Marla Dubinsky, Adam Cheifetz, Gil Melmed
Summary: This study aimed to assess whether VAT burden may be associated with infliximab cutoffs associated with efficacy in patients with IBD. The results suggest that patients with higher visceral adipose tissue burden may benefit from achieving higher infliximab levels to achieve remission.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Christina Lee, Tyson J. J. Sievers, Byron P. P. Vaughn
Summary: This study investigates physicians' practice patterns at the time of esophageal food impactions (EFI) and finds that endoscopists uncommonly take esophageal biopsies, which may delay the diagnosis and treatment of eosinophilic esophagitis (EOE).
JOURNAL OF CLINICAL MEDICINE
(2023)
Letter
Gastroenterology & Hepatology
Elizabeth S. Aby, Radha Rajasingham, Eva A. Enns, Byron P. Vaughn
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)